Oracle Unveils Oracle Clinical Development Analytics to Help Life Sciences Organizations Accelerate Drug Development

Oracle Unveils Oracle Clinical Development Analytics to Help Life Sciences Organizations Accelerate Drug Development--New Business Intelligence Application Provides Contract Research Organizations and Sponsors with Comprehensive View of Clinical Programs to Bolster Productivity, Reduce Costs

Redwood Shores, CA - January 13, 2010

Building on its commitment to help life sciences and healthcare organizations discover, develop, and market innovative products and services that prevent and cure disease, Oracle today announced Oracle® Clinical Development Analytics.

Oracle Clinical Development Analytics is a component of a rapidly expanding suite of business intelligence solutions - spanning clinical development, pre and post-marketing surveillance and healthcare - which are designed to provide critical insights for informed decision-making.

Oracle Clinical Development Analytics helps life sciences organizations drive their clinical programs more efficiently, obtain more timely access to information for informed decision making, and significantly increase the productivity of both their staff and sites.

Built on the proven Oracle Business Intelligence Suite Enterprise Edition Plus, Oracle Clinical Development Analytics helps life sciences organizations deliver actionable, near real-time insights across the entire clinical development process, including both active and previously completed trials.

The application enables life sciences organizations to accelerate study progress and makes it possible for them to achieve database lock faster. It helps companies improve clinical staff productivity by making it easier to identify non-performing sites.

From an organizational perspective, Oracle Clinical Development Analytics enables CROs and sponsors to provide greater transparency to one another in order to improve communication and better streamline activities.

The application's pre-built clinical warehouse and intuitive, ad-hoc report builder empower end users to rapidly build their own reports based on pre-calculated metrics.

The centralized warehousing architecture helps contract research organizations (CROs) as well as pharmaceutical, device, and biotechnology sponsors more effectively control IT costs by eliminating the need for multiple, disparate reporting systems.

Supporting Quotes
"Life Sciences organizations require systems that can improve the quality and timeliness of their clinical information to enhance the overall effectiveness of their programs," said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. "Oracle Clinical Development Analytics meets the industry need for a business intelligence application that helps life sciences executives, managers, and team members to make decisions based on current, consistent performance management information that has historically been dispersed across numerous sources and technologies."

"Working in conjunction with the Oracle Life Sciences Data Hub, Oracle Clinical Development Analytics is an additional piece in Oracle's increasingly comprehensive eClinical suite of offerings for life sciences. We see Oracle's increased focus on healthcare and life sciences as a shrewd business decision and its dedication to the creation of a comprehensive product offering as market leading," wrote Alan Louie, Research Director, IDC Health Insights, in a recent report.

Supporting Resources
Oracle Clinical Development Analytics Data Sheet
IDC Health Insights Report on Oracle Clinical Development Analytics
Oracle in Health Sciences
Follow Oracle Health Sciences on Twitter
Become an Oracle Health Sciences Fan on Facebook
Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry
About Oracle
Oracle (NASDAQ: ORCL) is the world's largest business software company. For more information about Oracle, please visit our Web site at http://www.oracle.com.

Trademarks
Oracle is a registered trademark of Oracle Corporation and/or its affiliates. Other names may be trademarks of their respective owners.
Contact Info
Kevin Ruane
Oracle
+1.650.506.6610
[email protected]

 Mary Tobin

O'Keeffe & Company

+1.503.658.7396
[email protected]

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.